Mayo Clinic medical consultants in hypertrophic cardiomyopathy, Jeffrey B. Geske, M.D., Steve R. Ommen, M.D., and Hartzell V. Schaff, M.D., focus on the latest publication of the "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy."
They evaluate the highest adjustments to the rule of thumb, together with the introduction of a cardiac myosin
inhibitor, mavacamten, for assist of individuals with symptomatic obstructive hypertrophic cardiomyopathy (HCM); the developed tips for wholesome ranges of train; the formal break up in sudden cardiac dying threat evaluation between kids and adults residing with HCM; and new recommendation on extra frequent screening for people who’ve threat components for atrial fibrillation.
Learn extra, https://www.mayoclinic.org/diseases-conditions/hypertrophic-cardiomyopathy/care-at-mayo-clinic/mac-20350208
From Mayo Clinic to your inbox, sign-up without cost: https://mayocl.in/3e71zfi
Visit Mayo Clinic: https://www.mayoclinic.org/appointments?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=TNSvQBCdu4U&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/
Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/
Follow Mayo Clinic on X, previously Twitter: https://x.com/MayoClinic
Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
